Systematic review evaluates Ecopipam's effects on involuntary tics in Tourette syndrome, indicating safety and tolerability.
We aimed to evaluate Ecopipam's efficacy and safety in reducing involuntary tics in TS according to different scales, such as the Yale Global Tic Severity Scale (YGTSS), the Clinical Global Impression of Improvement (CGI-Improvement), and the CGI-Severity scale. Furthermore, we gave information about the drug's safety profile and tolerability.
No takes yet. Share an insight, caveat, or question.
Darwish et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: